MYRIAD
INVESTOR
RELATIONS
  Myriad
     
 
   

Investor Relations


Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City
Utah 84108, U.S.A.
Phone: 801-584-3600
Fax: 801-584-3640
E-Mail: info@myriad.com

Myriad Genetics is a leading biopharmaceutical company focused on the development of novel healthcare products. Myriad has a full pipeline of preclinical drug candidates in development including two Phase I human clinical trials for cancer drugs, Azixaâ„¢ and MPC-2130. The Company markets molecular diagnostic tests to determine the risk of breast cancer, ovarian cancer, colon cancer, endometrial cancer and melanoma skin cancer in individuals with a family history of cancer.

  
Print Print     Email Email

Stock Information

NASD:MYGN
$61.31   + 1.52
Dec 4, 2008
1:47 PM ET
Quotes delayed at least 20 minutes. Information provided by eSignal.
  

© 2008 Myriad Genetics, Inc.